UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111) C.S. Tam | M. Wang | D. Simpson | S. Opat | G. Cull | J. Munoz | T.J. Phillips | W. Kim | S. Atwal | R. Wei | J. Huang | R. Elstrom | J. Trotman Department of Haematology, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Victoria, Australia; Department of Lymphoma & Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, United States; Waitemata DHB Haematology Service, North Shore Hospital, Auckland, New Zealand; Clinical Haematology, Monash Health, Monash University, Clayton, Victoria, Australia; Department of Haematology, Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia; Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, United States; Michigan Medicine Hematology Clinic, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Research and Development Center, BeiGene (Beijing) Co., Ltd, Beijing, China; BeiGene USA, Inc., San Mateo, United States; Department of Haematology, Concord Repatriation Hospital, The University of Sydney, Concord, NSW, Australia